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The recent progress in the chemotherapy of infectious disease is
notably deficient in regard to disorders of virus etiology. It has been
suggested that this may be due to the intracellular nature and the
metabolic interrelations with host cells that characterize virus infection;
and that these characteristics serve to make the parasite invulnerable
to chemical agents which are not at the same time toxic to the host
cells. Although the view is no longer widely held, effective chemother-
apeutic virucidal agents are significantly lacking.1
Numerous agents, e.g., urea,guanidine,propyleneglycol, and various
detergents, are known to inactivate readily or destroy certain viruses
in vitro. These substances, however, have been uniformly ineffective in
thehostbecauseoftoxicity, inactivation in vivo, or failure to penetrate to
the intracellular location of the virus in parasitized cells. There is no
evidence that these drugs prevent the spread of the virus in the host;
thus they are apparently ineffective even against the organism unpro-
tected by cell barriers.1
The well-known approach through metabolite antagonists has been
attempted, with but limited success. Several of the sulfonamides are re-
ported to be somewhat effective in infections caused by the psittacosis-
lymphogranuloma group.' lb 17 This group has been shown to be
susceptible also to the action of penicillin.", 17 It has been considered
that the effectiveness of antibacterial agents against these large viruses
is further evidence of their close phylogenetic relation to larger micro-
organisms. As for the smaller viruses, an attempt to alter the course of
experimental poliomyelitis in mice by means of antagonistic analogs of
naturally occurring pyrimidines yielded only questionable results.9
Another approach, made by Fitzgerald et al., pointed out the anti-
viral (phage) effect of certain of a group of acridines (especially
phosphine GRN-2-amino-9- (p-aminophenyl) acridinium chloride).'
* From the Departments of Bacteriology and of Pharmacology, Yale University School
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The interesting feature of these compounds was the reversal of their
activity by ribose nucleic acid.4 Since the viruses maintain the serological
specificity of their nucleoproteins even within the host cells, this was
apparently a means of interfering with the nucleic acid metabolism
(reproduction) of the organism. Andrewes suggests that the acidic
phosphate groups of nucleic acids are the primary points of attachment
of the acridines.' In practical application, however, the acridines have
been disappointing.
Another attempt to affect the virus was made through specific
enzyme inhibition by the use of certain arsenicals known to be -SH
enzyme inhibitors. Some success in the treatment of experimental
poliomyelitis in mice has been claimed for neoarsphenamine and several
other arsenicals."0
The most recent contribution to the field of virus chemotherapy
has resulted from an unique approach by Horsfall and McCarty.' These
investigators have demonstrated that certain polysaccharide prepara-
tions of bacterial origin, as well as similar materials from other sources,
are capable of modifying the course of infection with pneumonia virus
of mice.
The recent demonstration of the interesting biological specificities
of the antibiotic lactones and other synthetic analogs8' 12 prompted an
investigation of the activity of these agents in experimental virus in-
fection. In view of the previous general lack of success in the field of
virus chemotherapy, it seemed worthwhile to present the results ob-
tained with some twenty-four compounds of this series, even though
the study is yet in an early stage.
Methods and materials
The PR-8 strain of influenza A was obtained from Dr. E. W. Shrigley, De-
partment of Bacteriology, Yale University School of Medicine. We are indebted
to him for advice and assistance in the use of this organism.
The virus was carried in the Webster strain of white mice. Serial transfers
were made on the fifth day after infection.
The inoculum for the experimental groups of animals was obtained in the
following manner. Mice which had been infected five days previously were
killed with chloroform and autopsied. Lungs which showed the characteristic
plum-colored appearance of infection were excised and carefully ground in
sterile sand and 2 cc. of saline for a period of 10 to 15 minutes. A total of 5 cc.
of saline per lung was finally added and the mixture was allowed to sediment.
The supernatant fluid was removed and centrifuged at 1000 r.p.m. for 5
minutes. Again the supernatant material was removed and then stored at 40 C.
until needed.
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The experimental animals were all of the same sex and age, and weighed
between 18 and 22 gm. Individual mice were selected at random for infection
from a single pooled group. Each mouse was lightly anesthetized with ether and
0.05 cc. of a 1:50 dilution of the virus suspension were administered intranasally
at a rate designed to cause a minimum of respiratory difficulty. The mice used
for virus potency titration, i.e., by giving 10-fold graded dilutions of the
suspension, were infected last, in order to compensate for maximum deterioration
of the virus preparation.
The infected test animals were segregated in a large cage and set aside for
24 hours. At the end of this time they were withdrawn in small groups at random
and given the various drug treatments.
All the compounds freely soluble in water were used in 5 per cent aqueous
solutions, injected intraperitoneally. The other agents were emulsified with a
cholesterol-lecithin peanut oil medium* to form a stable 5 per cent suspension,
and injected subcutaneously. The various regimens of administration are re-
corded in table 1.
The effects were measured in two ways. First, the times of death of the con-
trols and of the treated groups were recorded up to 21 days, after which
time the surviving animals were considered cured. Mice that died within the
experimental period were examined for signs of pulmonary influenza. The mean
per cent surviving was calculated in each of the ten-day intervals following the
time of the first death in the control groups. This provided a second measure
of delay in time of death for those groups not having a significant number
of final survivors.
Experimentation andresults
A summary of the results is presented in table 1. The data were
obtained from five separate experiments each of which entailed an
arbitrary level of infection resulting from an attempt to achieve 100
per cent mortality in the control group.
After the first experiment, the compounds most promising in
therapeutic effect were retested, using different routes of administration
and dosage schedules with the objective of producing high and pro-
longed blood levels.
Unfortunately, the level of infection was not constant, thereby
increasing the number of variables and causing great difficulty in cal-
culation of statistical reproducibility, because no satisfactory error term
could be ascertained. The results must therefore be taken only as in-
dications rather than as an exact measure of activity with a definite
probability ofchance occurrence.
As might be expected, the efficacy of the drugs decreased with an
increased level of infection. But even when more than 10,000 LD50..
* This material was freely supplied to us by Endo Products, Inc., under the trade
name "Pendil."
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of the virus were given, a distinct difference in survival time could be
seen with some drugs, although all the animals eventually succumbed
to the massive infection. With lesser infections, however, there always
was a greater number of final survivors in groups which showed an
average survival time greater than that of the controls.
In seven different experimental groups treated with butyrolactone a
positive therapeutic effect was always observed. The most desirable
results were obtained with repeated doses of 200 mg./kg. given in-
traperitoneally. Subcutaneous treatment with 150 mg.//kg. twice daily
for 5 days also produced effective cures.
Other compounds like gamma-valerolactone, 3-phenyl-2-butene-1,4-
olide, parasorbic acid, and 6-methoxy-8-(2,5-dimethylpyrryl-l)-
quinoline had some therapeutic effect in several trials.
Some of the agents like tetrahydrofuran, 5-nitro-2-furfuraldehyde
semicarbazone,* 3-methyl-5-carboxy-2-pentene-1 4-olide, isoclavacin,
and aspergillic acid showed promise in single trials, but have not yet
been rechecked.
The other furans were without effect, as were the angelica lactones
and the other gamma unsaturated lactones. In some cases, such as
clavacin and methyl furan, there was noticeable evidence of drug
toxicity at the dose level utilized so that the apparent inactivity of
these drugs is questionable.
The most inconsistent results were obtained with anemonin, the
antibiotic agent from the Ranunculaceae. This material is notably un-
stable in vivo and is fairly toxic. The more concentrated dosage regime
probably produced some toxicity.
Discussion
The inability to produce 100 per cent mortality in all controls or
at least to reproduce the same level of infection in all experiments
made it impossible to compute the statistical significance of the results.
Repeated experiments, however, tended to substantiate the therapeutic
efficacy of some of these compounds.
From the data it is not possible to draw many biochemorphic
conclusions. Generally, the most outstanding trend was in that the
saturatedcompounds seemed tobemore active than were the unsaturated
ones. This is quite unexpected since it contrasts sharply with the results
* This material is marketed under the trade name "Furacin" by the Eaton Labo-
ratories, Inc.
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obtained with these compounds against bacteria and protozoa. "2 It
isalsoin disagreementwithVeldstra'sconcepts aboutchemical structures
which confer growth inhibitory properties.18
Methylation seems to cause a loss of activity as may be seen by com-
paring gamma-valerolactone with butyrolactone and dimethyl-
isoclavacin with isoclavacin.
Wherever unsaturated compounds were effective it appears that
the double bond in the 2-position is much more conducive to activity
than that in the 3-position. This becomes evident by noting the activity
of isoclavacin and 3-methyl-5-carboxy-2-pentene-1,4-olide as compared
with clavacin and 3-pentene-1,4-olide.
Again in the furan series, it becomes apparent that the 5-nitro sub-
stituent is necessary for any pronounced biological activity.
The importance of the respective chemical groups, however, cannot
be confidently stated before more careful quantitative techniques are
utilized.
It is of interest to note that the therapeutic effects seen here were
obtained after infection had been allowed to progress to a fairly ad-
vanced stage. Under these conditions, the efficacy of Horsfall and
McCarty's polysaccharides,'1 which have definite prophylactic effect,
would be reduced to insignificance.
The activity of butyrolactone is also interesting in view of its ability
to cause complete suppression of cortical activity as measured by the
EEG5 and to produce in mice and chickens a reversible inhibition of
voluntary movements at sublethal doses.* If these phenomena can be
interpreted as a type of anesthetic property, then the rather marked
efficacy of butyrolactone in these influenza virus infections bears a
striking relationship to the antiviral properties of anesthetic agents,
like diethyl ether, recently reported by Sulkin.13 14
Conclusions
1. Twenty-four compounds were tested for their chemotherapeutic
properties in experimental influenza (PR-8) infection in mice.
2. Mostof these agents were of the group of antibiotic lactones and
their synthetic analogs.
3. Butyrolactone, 6-methoxy-8-(2, 5-dimethylpyrryl-l)-quinoline,
3-phenyl-2-butene-1,4-olide, 3-methyl-5-carboxy-2-pentene-1,4-olide,
* Unpublished data of N. J. Giarman.
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parasorbic acid, and isoclavacin seemed to produce marked therapeutic
effects.
4. An attempt is made to relate chemical structure to chemo-
therapeutic activity.
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THE TREATMENT OF EXPERIMENTAL INFLUENZA IN MICE
Compound Formula Route-dose Duration I No. Efiect, treated minas cont-rols L.D.6,,
(source) mg. perkg. of of % mean survivors % final survivors level of
treatment mice infection
i.p.
- 400 single 8 18.0 10.0
7-butyro. i.p.
- 200 qd
- 5x 7 41.9 47.1 100-1000
lactone i.p.
- 100 tid
- 15x 10 19.0 10.0 10-100
i.p.
- 100 tid
- 15x 20 20.0 30.0
(Cliffs-Dow) i.p.
- 150 bid
- lOx 20 9.5 0 10000
s.c.
- 150 bid
- lOx 20 3.3 0 10000
s.c.
- 150 bid
- lOx 20 17.5 25.0
'Y-valero. i.p.
- 500 single 5 30.0 30.0
lactone 0 i.p.
- 250 qd
- 5x 7 18.0 18.6 100-1000
(Monsanto)
Tetrahydro-
furan i.p.
- 100 single 5 12.0 0 10000
(DuPont)
Tetrahydro-
furfuryl C.Hto" i.p.
- 500 qd
- 5x 10 2.0 -10.0 alcohol
(Quaker)
Methyl furan S.C.
- 100 single 5 -38.0 -30.0
(Quaker) 0 CH3
Furfuryl
alcohol F-10420" i.p.
- 150 single 5 -12.0 -10.0
(Quaker)
Furfural i.p.
- 150 single 7 -13.0 -30.0 (Quaker) CHO
5-nitro-2.
furfuraidehyde
Oald C'BNNMCONMt s.c.
- 500 single 7 10.0 semicarbazone 0 13.0
(Eaton)
3-pentene
1,4-olide
(Calco and CHS i.p. 300 single 5 -28.0 -30.0
Winthrop)
0
2-pentene
1,4-olide i.p.
- 150 single 6 -8.0 -13.3 (Calco and 0 C143
Winthrop)
3-phenyl- 2-butene. S.C.
- 500 single 5 28.0 10.0
1,4-olide S.C.
- 100 qd
- 5x 7 39.0 47.1 100-1000
(Winthrop) 0 S.C.
- 100 bid
- lOx 10 7.0 10.0 10-100
3-methyl-5- Hs carboxy-2- i.p.
- 100 single 5 34.0 50.0
pentene- 0 "acooll S.C.
- 100 qd
- 5x 7 18.0 18.6 100-1000 1,4-olide
4z keto Jo*
c H dimethylacryl) p i.p.
- 24 single 5 2.0 butyrolactone 10.0
(Vick)
cml
0
Anemonin 0 S.C. 250 single 5 20.0 30.0
100-1000 (Bergmann) 0 S.C. 100 qd
- 5x 8 -8.0 -10.0 10
Clavacin
i.p. 7.5 single 5 -46.0 -30.0 (Vick and
Raistrick) 0
0
C)
5 12.0 10.0 Isoclavacin i.p. 25 single (Vick)
CH3 "SC
Dimethyl- c 0
i.p. 25 single 5 -8.0 -10.0 (Vick)
0
Dimethyl MN 0
10000 hydantoin
0 i.p.
- 100 qd
- 5x 10 5.0 0 (DuPont)
1,5-hexanolide i.p.
- 500 qd
- 5x 10 -43.0 -40.0 (Calco) i.p.
- 250 bid
- lOx 5 0 10.0 CH3
0
Parasorbic i.p.
- 500 single 5 18.0 30.0 acid
S.C. 100 qd
- 5x 6 17.0 23.3 100-1000 (Calco) 3
0
6-methoxy-8- "3C (2,5 dimethyl s.c.
- 500 single 5 36.0 50.0
pyrryl-I) 4 S.C.
- 100 qd
- 5x 7 37.6 33.0 100-1000 quinoline S.C.
- 100 bid lOx 9 11.3 0 10-100 (Gilman)
Prodigiosin N
tartrate s.c.
- 500 single 5 -2.0 10.0 zz
Gramicidin i.p.
- 1.0 single 7 3.0 -i.4
Aspe illic 1.p
- 25 single 7 13.0 12.9 acid